HTA Systems Compared: NICE, G-BA, HAS, AIFA – How They Differ

A market access team prepares an HTA submission for a new oncology drug. They build a dossier with strong clinical trial data, a cost-effectiveness model, and budget impact analysis. The submission goes to NICE in the UK, and they receive a positive recommendation. They use the same core dossier for G-BA in Germany. The outcome: no additional benefit over the comparator.

Same drug. Same data. Different HTA bodies. Different conclusions. This happens regularly because NICE and G-BA evaluate drugs through fundamentally different frameworks. Understanding how each major European HTA body works – what they prioritize, what evidence they require, and how their decisions translate into market access – is essential for any team launching in Europe.

This article compares the four most influential European HTA systems: NICE (UK), G-BA (Germany), HAS (France), and AIFA (Italy).

The Problem: One Dossier Does Not Fit All

The most common market access mistake in European launches is treating HTA submissions as a single exercise with regional variations. In reality, each HTA body operates under a different legal framework, uses different evaluation criteria, and weighs different types of evidence.

According to NICE, approximately 30% of drugs submitted receive a restricted recommendation on the first review.

Three structural differences create the challenge:

Different comparators. NICE typically accepts a standard of care comparator. G-BA requires the company to demonstrate benefit against a comparator they specify – which may not be the one used in your pivotal trial.

Different evidence preferences. NICE relies heavily on cost-effectiveness analysis (QALY-based). G-BA focuses on clinical added benefit without formal cost-effectiveness modeling.

Different timelines and consequences. In Germany, a drug can launch at a free price on Day 1 of approval, but the AMNOG assessment determines the negotiated price. In the UK, the NICE decision determines whether the NHS will pay for the drug at all.

The Insight: How Each System Actually Works

The real insight: NICE and G-BA are the two most influential HTA bodies globally because their decisions affect pricing in dozens of other countries through international reference pricing. A positive NICE recommendation enables premium pricing. A poor G-BA rating forces a lower negotiated price in Germany, which cascades through reference pricing to other EU markets.

Decision Intelligence: Tailoring Your Strategy by HTA Body

The Solution: Parallel HTA Strategy

Leading market access teams plan for all four bodies simultaneously, starting 18-24 months before expected approval. This means:

Early scientific advice. Seek NICE scientific advice and G-BA consultation during Phase 3. These meetings reveal what each body considers strong evidence.

Comparator alignment. Design clinical programs with G-BA’s Appropriate Comparative Therapy (ACT) in mind. A trial designed only around the US clinical endpoint may not satisfy European HTA requirements.

Parallel dossier development. Build a core value dossier with modular components tailored to each HTA body’s requirements.

The Value: What HTA Literacy Delivers

Faster access. Teams that prepare HTA-aligned evidence achieve positive recommendations 6-12 months faster.

Better pricing. Positive HTA outcomes in the UK and Germany anchor higher prices across Europe.

Fewer surprises. Early HTA engagement eliminates the most common failure mode: submitting evidence that does not match what the body needs.

Example: Same Drug, Different HTA Outcomes

A rare disease drug launches in 2024. The team seeks NICE scientific advice early, builds a cost-effectiveness model showing acceptable ICER with a managed access agreement, and receives a positive recommendation. For G-BA, they ensure their Phase 3 trial includes the specified comparator and demonstrate “considerable additional benefit.” Result: premium pricing maintained.

A competitor launches in the same indication six months later. They did not seek early HTA advice, used a different comparator in their pivotal trial, and submitted a standard global dossier. NICE gives a restricted recommendation. G-BA assigns “no additional benefit proven.” Their European pricing is 40% below the first company.

Conclusion

NICE, G-BA, HAS, and AIFA evaluate drugs through different frameworks. NICE centers on cost-effectiveness. G-BA focuses on clinical added benefit against a specified comparator. HAS uses medical benefit ratings. AIFA combines clinical value with budget impact.

For market access teams, the most important action is engaging early with NICE and G-BA, and designing clinical programs that produce evidence aligned with what each body requires. These two decisions have more impact on European pricing than any other market access activity.

Go deeper on market access strategy. Explore market access fundamentals and learn how international reference pricing connects HTA decisions across markets.

Frequently Asked Questions

How to Prepare a Multi-Country HTA Value Dossier

A value dossier is the core submission document for HTA review. Preparing one that works effectively across multiple markets requires three things. First, a common evidence base: the clinical data from your pivotal trial is the foundation – ensure it is GCP-compliant, appropriately powered, and uses clinically meaningful endpoints rather than surrogate measures (NICE and most HTA bodies increasingly reject surrogate-only endpoints). Second, country-specific economic models: cost-effectiveness models require country-specific unit costs (hospitalisation costs, treatment costs, productivity values) and appropriate comparators. A UK model is not the same as a German model. Third, patient perspectives: many HTA bodies now require or heavily weight patient-reported outcome data and real-world evidence from similar countries. Engage patient advocacy groups early.

The NICE Managed Entry Agreement Process: When Standard Approval Is Not Available

When a drug does not clearly meet NICE’s cost-effectiveness threshold but has promising data, NICE may approve it via a Managed Entry Agreement (MEA) – also called a Patient Access Scheme. Two main types: simple discounts (the company agrees to provide the drug at a lower effective price through rebates, confidential to protect international reference prices), and outcome-based schemes (the company refunds NHS costs if the drug does not achieve agreed real-world outcomes). MEAs are common for oncology drugs where Phase 3 data shows survival benefit but overall evidence maturity is limited. They allow immediate patient access while the evidence base matures.